Expired activity
Please go to the PowerPak homepage and select a course.

New Directions for Oral Treatment in B-Cell Malignancies: Implications for Pharmacists

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE), accredited by Purdue University, and supported by an educational grant from AbbVie and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.


Anthony J. Perissinotti, PharmD, BCOP
Clinical Team Lead, Hematology/Oncology
Clinical Pharmacist Specialist, Inpatient Hematology
The University of Michigan – Michigan Medicine
Adjunct Clinical Assistant Professor
The University of Michigan College of Pharmacy
Ann Arbor, MI

Victoria R. Nachar, PharmD, BCOP
Clinical Pharmacist Specialist, Ambulatory Hematology Oncology
University of Michigan– Michigan Medicine, Rogel Cancer Center
Adjunct Clinical Assistant Professor
University of Michigan College of Pharmacy
Ann Arbor, MI


Drs. Perissinotti and Nachar hereby state that they have no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.

The following reviewer, Ashley Glode, PharmD, hereby states that she has no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.

Susanne Batesko, RN, BSN, Robin Soboti, R.Ph, and Susan R. Grady, MSN, RN-BC, as well as the planners, managers, reviewers, Purdue staff and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


acpePharmacist Accreditation Statement - Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is an application based, continuing education activity of Purdue University, an equal access/equal opportunity institution.
UAN: 0018-9999-20-021-H01-P
Credits: 1.0 hours (0.1 ceu)

Type of Activity: Application 
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 60 minutes


August 21, 2020


August 21, 2021


This accredited activity has been designed for oncology, managed care and specialty pharmacists.


During the period August 21, 2020 to August 21, 2021 participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


To educate and inform oncology, managed care, and specialty pharmacists on how to optimally manage patients with B-cell malignancies receiving oral treatment, including ensuring appropriate access to patient-specific treatments, developing optimal toxicity prevention and management, and providing enhanced pharmaceutical care thus leading to optimized outcomes.

Proposed Learning Objectives

At the conclusion of the continuing pharmacy education activities, the learner will be able to:

  • Discuss the current guideline recommendations for the treatment of B-cell malignancies
  • Appraise the mechanism of action, efficacy and safety of current and emerging oral treatment options for B-cell malignancies
  • Demonstrate strategies to effectively counsel patients receiving oral therapy for the treatment of B-cell malignancies, including assessment and management of adverse effects, and education for promoting safe use and adherence to treatment

Additional References

» Slide (PDF)


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Purdue University, Postgraduate Healthcare Education, LLC, Pharmacyclics LLC, an AbbVie Company, Janssen Biotech, Inc. or Janssen Scientific Affairs, LLC. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.